Kivizidiale

Timolol and Travoprost, the active ingredients in Kivizidiale, are a beta‑blocker and prostaglandin analog presented as eye drops for ocular use. They are employed to lower intra‑ocular pressure in patients with open‑angle glaucoma and ocular hypertension. GNH USA supplies Kivizidiale as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kivizidiale combines timolol and travoprost to reduce intra‑ocular pressure in glaucoma‑related conditions.

Open‑angle glaucoma: lowers pressure to slow optic nerve damage. Ocular hypertension: reduces pressure to prevent progression to glaucoma. Post‑surgical ocular hypertension: assists in maintaining target pressure after eye surgery.

Kivizidiale may cause ocular and systemic reactions.

Common Side Effects: - Eye irritation or burning sensation. - Blurred vision shortly after instillation. - Redness of the conjunctiva. - Dry eye or foreign‑body feeling. - Mild headache. - Transient eyelash changes.

Serious or Rare Side Effects: - Severe allergic reaction with swelling or rash. - Sudden loss of vision. - Marked eye pain or inflammation. - Paradoxical increase in intra‑ocular pressure. - Systemic bradycardia or hypotension. - Exacerbation of asthma or COPD.

Before prescribing Kivizidiale, clinicians should consider several safety aspects. - Assess cardiovascular status: timolol may lower heart rate and blood pressure. - Screen for respiratory disease: avoid in patients with asthma or severe COPD. - Monitor intra‑ocular pressure regularly to ensure therapeutic response. - Advise patients not to wear contact lenses immediately after dosing. - Use only if benefits outweigh risks during pregnancy or lactation. - Store at room temperature: keep in the original container, protect from light and moisture.

Kivizidiale can interact with other medications, requiring careful management.

Major Interactions (Avoid): - Non‑selective systemic beta‑blockers (e.g., propranolol): additive bradycardic effects. - Sympathomimetic ophthalmic agents (e.g., phenylephrine): may diminish pressure‑lowering efficacy.

Moderate Interactions (Monitor Closely):\n- Other ocular hypotensive agents (e.g., latanoprost): increased risk of ocular irritation. - Topical anesthetics: potential corneal toxicity. - Systemic antihypertensives: may enhance timolol‑induced blood pressure reduction.